- TOP
- Agaricus
Agaricus | Sun Chlorella Lab
Anti-tumor action, liver damage inhibition action, by
The Beginning of Agaricus Study
In 1965, a mushroom was sent from Brazil to Dr. Inosuke Iwade at Mie University in Japan.
This mushroom was called Agaricus Blazei.
Initially, Dr. Iwade challenged the artificial culture of the mushroom, and he made mass production possible for the first time in the world in 1975, which was ten years after his personal study.
Dr. Hitoshi Ito was conducting anti-cancer examinations on various mushrooms at the Mie University and a person who had cancer came to hear about his work. After being inspired, Dr. Ito began to conduct research immediately.
Agaricus blazei (Himematsutake)
The positive results were released by the Japanese Cancer Association in 1980, and became widely known to the public.
Later on, the mushrooms scientific name was discovered, and the paper was published under the scientific name Agaricus blazei Murrill (Japanese name: Himematsutake) in 1982. Since then, Dr. Ito has published more than 80 articles.
Iwade strain 101 – The longest history of study and cultivation
Dr. Ito fell in love with the wonder of Agaricus blazei (Himematsutake) and his expertise resulted in continued research on the anti-cancer effect of several mushrooms over the years; mushroom is mutable and the medicinal properties also change with the cultivation environment.
Agaricus blazei (Iwade strain 101) is the strain which has the highest cultivation of anti-cancer activity, and grows within a cultivation environment to not produce a mutation. It has the longest history of study and cultivation.
Report on the effects
・Anti-cancer action
・Cancer transition inhibitory action
・Liver-problems inhibitory action
・Cholesterol-lowering action
・Serum hypoglycemic action
・Immunostimulatory action
・Blood-sugar ascension retardation
・Anti-allergic action
・Arteriosclerosis prevention
・Cardiopathy prevention
・Anti-oxidant action, etc.
Is the clinical study conducted?
Dr. Kikuo Nomoto, a leading member of a well-known medical congress began a Non Profit Organization called Hibireimeijuku. This organization conducted several clinical studies with terminal cancer patients. Dr. Nomoto chose the Agaricus blazei (Himematsutake) Iwade strain 101 to use in his study program.
The studies included terminal cancer patients given only one month to live. You will find details of the studies on the website: http://www.hibireimei.com/hm.pdf of Hibireimeijuku.
Misleading information on Agaricus
There are hundreds of mushrooms within the Agaricus genus - even the scientific name of the popular white mushroom is Agaricus bisporus (Lange) Sing, a family of the Agaricus genus.
Agaricus blazei (Himematsutake), one of the Agaricus genus and its various medicinal effects have been well researched, but not all Agaricus mushrooms are the same. The active constituents of mushrooms vary depending on the growing environment and cultivation conditions. Agaricus blazei (Himematsutake) has typically been the one that has been reported on the most at academic conferences.
β-(1→6)-D-glucan, a polysaccharide of Agaricus blazei (Himematsutake), is bound to protein more than any other mushroom, and is easily absorbed (by eating & brewing) into the body through the gastrointestinal tract. If not properly absorbed, there is no point to have the active constituents in the first place.
About Safety
In February 2006, an announcement made by the Ministry of Health, Labour and Welfare found a carcinogenic promoting effect in one Agaricus product from a specific manufacturer. The subsequent investigation revealed no problem with the other Agaricus products, but the market was confused by the media report in error that ‘Agaricus is dangerous.’
Most importantly, there was only “one product (produced by one company) that had a carcinogenic promoting effect.” Other products using ingredients with proper quality control and safety procedures present no danger whatsoever. Iwade strain 101 is strictly controlled from culturing to the finished product.
Hitoshi Ito, MD, PhD
Dr. Hitoshi Ito
MD, PhD
President of Fungus Product Pharmacology Institute.
Specialties: Study on anti-cancer products of fungi (mushrooms) and marine plants (seaweed) focusing on their potential to activate host resistance.
A Message from Dr. Ito
I was doing research on food poisoning in school. One day, my friend told me that his sister recovered from her terminal cancer by taking a mushroom, which inspired me to start studying the anti-cancer mushrooms just for fun. That was the end of 1963.
It was descovered that the cancer transplanted to mice actually faded away. This study was soon discovered by my supervisor and accepted as my formal research subject a year later.
It was in 1978 that I discovered Himematsutake (Agaricus blazei Murrill) and since then I have continued to study this unique mushroom in order to report the superlative & distinguished medicinal effect to the public. Up to now, my academic life has been dedicated to anti-cancer products derived from nature such as fungi (mushrooms) and marine plants (seaweed), but I have not discovered any of which is more superior than Himematsutake (Agaricus blazei Murrill).
- 2006/08/21
- Bellini M. F.:In vitro Matabolism effect on Genotoxicity and Antigenotoxicity of Agaricus blazei organics and aqueous extracts by the Comet Assay.,Cytologia,71(3),205-211,2006
